My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Altimmune, Inc. - Common Stock (NQ:ALT)

3.950 +0.040 (+1.02%)
Streaming Delayed Price Updated: 3:24 PM EDT, Oct 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,529,011
Open 3.930
Bid (Size) 3.940 (42)
Ask (Size) 3.950 (76)
Prev. Close 3.910
Today's Range 3.850 - 3.960
52wk Range 2.900 - 11.16
Shares Outstanding 85,076,300
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune
From Faruqi & Faruqi, LLP
Via Business Wire
ALTIMMUNE FINAL DEADLINE REMINDER: Bragar Eagel & Squire, P.C. Urges Investors to Contact the Firm Regarding the October 6th Deadline
From Bragar Eagel & Squire
Via GlobeNewswire

Performance

YTD
-44.4%
-44.4%
1 Month
+4.5%
+4.5%
3 Month
-10.8%
-10.8%
6 Month
-0.8%
-0.8%
1 Year
-35.2%
-35.2%

More News

Read More
Levi & Korsinsky Reminds Altimmune Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 6, 2025 - ALT
Via NewMediaWire
Topics Fraud Lawsuit
Levi & Korsinsky Reminds Altimmune Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 6, 2025 - ALT
Via TheNewswire.com
Topics Fraud Lawsuit
ALT INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune
From Faruqi & Faruqi LLP
Via GlobeNewswire
ALTIMMUNE CLASS ACTION REMINDER: Bragar Eagel & Squire, P.C. Reminds Investors of October 6th Deadline and Urges Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Altimmune, Inc. Class Action: Levi & Korsinsky Reminds Altimmune Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 6, 2025 - ALT
Via NewMediaWire
Topics Fraud Lawsuit
Altimmune, Inc. Class Action: Levi & Korsinsky Reminds Altimmune Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 6, 2025 - ALT
Via TheNewswire.com
Topics Fraud Lawsuit
Contact Levi & Korsinsky by October 6, 2025 Deadline to Join Class Action Against Altimmune, Inc. (ALT)
Via NewMediaWire
Topics Fraud Lawsuit
Contact Levi & Korsinsky by October 6, 2025 Deadline to Join Class Action Against Altimmune, Inc. (ALT)
Via TheNewswire.com
Topics Fraud Lawsuit
ALT DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important October 6 Deadline in Securities Class Action - ALT
From The Rosen Law Firm PA
Via GlobeNewswire
Altimmune, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – ALT
From DJS Law Group
Via Business Wire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune
From Faruqi & Faruqi LLP
Via GlobeNewswire
DEADLINE APPROACHING: Berger Montague Advises Altimmune, Inc. (NASDAQ: ALT) Investors to Inquire About a Securities Fraud Class Action by October 6, 2025
From Berger Montague
Via GlobeNewswire
Altimmune, Inc. Class Action: Levi & Korsinsky Reminds Altimmune Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 6, 2025 - ALT
Via NewMediaWire
Topics Fraud Lawsuit
Altimmune, Inc. Class Action: Levi & Korsinsky Reminds Altimmune Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 6, 2025 - ALT
Via TheNewswire.com
Topics Fraud Lawsuit
ALTIMMUNE (ALT) DEADLINE ALERT: Bragar Eagel & Squire, P.C. Urges Investors to Contact the Firm Before the October 6th Deadline in the Altimmune Class Action Lawsuit
From Bragar Eagel & Squire
Via GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Investors Who Lost Money on Altimmune, Inc. (ALT) Should Contact Levi & Korsinsky About Pending Class Action - ALT
Via NewMediaWire
Topics Fraud Lawsuit
Investors Who Lost Money on Altimmune, Inc. (ALT) Should Contact Levi & Korsinsky About Pending Class Action - ALT
Via TheNewswire.com
Topics Fraud Lawsuit
ALT DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important October 6 Deadline in Securities Class Action - ALT
From The Rosen Law Firm PA
Via GlobeNewswire
Altimmune, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ALT
Via NewMediaWire
Topics Fraud Lawsuit
Altimmune, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ALT
Via TheNewswire.com
Topics Fraud Lawsuit
Shareholders of Altimmune, Inc. Should Contact Levi & Korsinsky Before October 6, 2025 to Discuss Your Rights - ALT
Via NewMediaWire
Topics Fraud Lawsuit
Shareholders of Altimmune, Inc. Should Contact Levi & Korsinsky Before October 6, 2025 to Discuss Your Rights - ALT
Via TheNewswire.com
Topics Fraud Lawsuit

Frequently Asked Questions

Is Altimmune, Inc. - Common Stock publicly traded?
Yes, Altimmune, Inc. - Common Stock is publicly traded.
What exchange does Altimmune, Inc. - Common Stock trade on?
Altimmune, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Altimmune, Inc. - Common Stock?
The ticker symbol for Altimmune, Inc. - Common Stock is ALT on the Nasdaq Stock Market
What is the current price of Altimmune, Inc. - Common Stock?
The current price of Altimmune, Inc. - Common Stock is 3.950
When was Altimmune, Inc. - Common Stock last traded?
The last trade of Altimmune, Inc. - Common Stock was at 10/06/25 03:24 PM ET
What is the market capitalization of Altimmune, Inc. - Common Stock?
The market capitalization of Altimmune, Inc. - Common Stock is 336.05M
How many shares of Altimmune, Inc. - Common Stock are outstanding?
Altimmune, Inc. - Common Stock has 336M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.